Retatrutide vs Mounjaro
Which Is Right for You? Complete Comparison (2026)
Compare Retatrutide (Triple Agonist) vs Mounjaro (Dual Agonist). See the weight loss data, mechanism of action, and clinical trial results.
Retatrutide vs Mounjaro: At a Glance
- ✓Triple agonist: GIP + GLP-1 + glucagon receptors
- ✓Glucagon component increases energy expenditure and fat oxidation
- ✓~24% weight loss at 48 weeks in phase 2 (12 mg dose)
- ✓Phase 3 trials ongoing — not yet FDA-approved
- ✓Developed by Eli Lilly
- ✓Dual GIP + GLP-1 receptor agonist — first in class
- ✓GIP agonism enhances insulin sensitivity in adipose tissue
- ✓~21% mean weight loss at 72 weeks (SURMOUNT-1, 15 mg)
- ✓GIP may moderate GI side effects vs GLP-1-only drugs
- ✓Half-life ~5 days — once-weekly injection
Detailed Comparison
| Feature | Retatrutide | Mounjaro |
|---|---|---|
| Mechanism | Triple GIP/GLP-1/glucagon receptor agonist | Dual GIP/GLP-1 receptor agonistBest |
| Dosing | 1-12 mg SC weekly (phase 2 doses) | 2.5-15 mg SC weekly |
| Administration | Subcutaneous injection weekly | Subcutaneous injection weekly |
| Half-life | ~6 days | ~5 days |
| FDA Status | Not FDA-approved — phase 3 clinical trials | FDA-approved: Mounjaro (T2D), Zepbound (obesity) |
| Key Trial | Jastreboff AM et al. NEJM 2023 — phase 2 obesity trial | Jastreboff AM et al. NEJM 2022 (SURMOUNT-1) — 20.9% weight loss |
| Side Effects | Nausea, diarrhea, vomiting, constipation (similar to other incretins) | Nausea (31%), vomiting, diarrhea, constipation |
Which Should You Choose?
Retatrutide (triple gip/glp-1/glucagon receptor agonist) and Tirzepatide (dual gip/glp-1 receptor agonist) serve different clinical roles despite both being in the Triple incretin agonist space. Retatrutide first triple incretin agonist targeting gip, glp-1, and glucagon receptors. Tirzepatide first-in-class dual gip and glp-1 receptor agonist that activates two incretin pathways for enhanced weight loss and glycemic control vs single agonists.
Whichever you choose, track your protocol in Shotlee to build clean data for dose optimization and outcomes comparison.
Retatrutide vs Mounjaro: Frequently Asked Questions
Retatrutide is a triple gip/glp-1/glucagon receptor agonist while Tirzepatide is a dual gip/glp-1 receptor agonist. They differ in mechanism, dosing, and clinical evidence. Your choice should depend on your specific goals and medical history.
Switching should be done under medical supervision. Your prescriber can advise on transition protocols. Track both in Shotlee for comparison data.
Retatrutide works as a triple gip/glp-1/glucagon receptor agonist (1-12 mg SC weekly (phase 2 doses)), while Tirzepatide is a dual gip/glp-1 receptor agonist (2.5-15 mg SC weekly). They have different half-lives (~6 days vs ~5 days), side effect profiles, and levels of clinical evidence.
Yes. Shotlee supports tracking any medication or peptide. You can compare your results across different protocols.
Track Retatrutide or Mounjaro in Shotlee
Free dose tracking, side effect logging, and outcome comparison for any medication protocol.
📚References & sources
Latest on Retatrutide
Retatrutide: The Next Frontier in Weight Loss and Its Profound Implications
Eli Lilly's experimental drug retatrutide is showing unprecedented weight loss results, pushing the boundaries of what's possible. But with great power comes great responsibility, and doctors are urging caution.
7 min read
Retatrutide's Rapid Weight Loss: Balancing Benefits and Risks
New-generation GLP-1 drugs like retatrutide promise unprecedented weight loss, but what are the implications for your body's composition and overall health? This article delves into the science, risks, and strategies for navigating rapid weight reduction.
8 min read
Retatrutide: The Next Wave in Metabolic Peptide Therapy?
Discover Retatrutide, a groundbreaking peptide with triple-receptor activity, poised to redefine metabolic health and weight management strategies. Learn about its science, potential, and what it means for the future of wellness.
8 min read